Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04349956|
Recruitment Status : Enrolling by invitation
First Posted : April 16, 2020
Last Update Posted : August 4, 2020
|Condition or disease||Intervention/treatment|
|Knee Osteoarthritis||Drug: UBX0101 or placebo|
|Study Type :||Observational|
|Estimated Enrollment :||180 participants|
|Official Title:||Long-Term Follow-Up Study of Patients With Moderate to Severe, Painful Osteoarthritis of the Knee Who Participated in a Randomized, Placebo-Controlled Study of UBX0101|
|Actual Study Start Date :||April 20, 2020|
|Estimated Primary Completion Date :||June 2021|
|Estimated Study Completion Date :||June 2021|
Patients from a randomized placebo-controlled study of UBX0101
Patients with moderate to severe, painful OA of the knee who participated in a randomized, placebo-controlled study of UBX0101.
Drug: UBX0101 or placebo
This is an observational study. No intervention is administered.
- Incidence of adverse events up to 1 additional year of follow up. [ Time Frame: 52 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04349956
|Study Director:||Medical Monitor||UNITY Biotechnology|